Project Grant R01CA315853
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $688K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $639,514 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on mechanistic characterization of benzothiazepinone inhibition of NVL (Norovirus-Like), an essential AAA+ adenosine triphosphatase (ATPase) enzyme involved in ribosomal large subunit (60S)...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $434,969 to the University of Pennsylvania through the Cancer Treatment Research program (CFDA 93.395) on May 1, 2026, for a five-year project period concluding April 30, 2031. The award supports fundamental research investigating the cellular mechanisms that sustain FLT3-mutant acute myeloid leukemia (AML) clone persistence during targeted kinase inhibitor therapy. The research combines genetically engineered...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...
- Federal Grant Award Summary Baylor College of Medicine received a $2.4 million Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective August 15, 2025 through July 31, 2029. The award funds research investigating the role of RNA sequestration in acute myeloid leukemia (AML), specifically examining how the RNA helicase DDX6 (DEAD-Box Helicase 6) regulates post-transcriptional processes critical to leukemia development and...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $431,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Albert Einstein College of Medicine, effective April 1, 2026, through March 31, 2028. This award funds research to investigate dual-targeting therapeutic approaches for acute myeloid leukemia (AML) by combining CD123-directed natural killer (NK) cell engagement with BCL-2 inhibition. The research examines the efficacy and molecular...
- Federal Project Grant Award Summary The University of Michigan, through its Office of Research and Sponsored Projects Division, received a $646,881 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports research focused on developing and validating small molecule inhibitors targeting ASH1L (Absent, Small or Homeotic 1-Like), a histone methyltransferase enzyme...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $885,632 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) beginning April 2, 2026, with a completion date of March 31, 2028. This research project focuses on interrogating the erythroid differentiation and BCL-XL (B-cell lymphoma-extra large) axis in TP53-mutated acute myeloid leukemia (AML). The research aims to develop and evaluate novel therapeutic...